Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis

Clinical and Experimental Immunology

Volumn 129, Issue 1, 2002, Pages 61-68

  Ohata, J ^a,b,d   Sakurai, J ^a   Saito, K ^a   Tani, K ^b,e   Asano, S ^b   Azuma, M ^a,c  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

Co stimulation; GVHD; GVL; IL 12; Tolerance

Indexed keywords

ALLOANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD80 LIGAND MONOCLONAL ANTIBODY; CD86 LIGAND MONOCLONAL ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; MESSENGER RNA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE RELEASE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HOST; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STIMULATION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; BONE MARROW TRANSPLANTATION; CD40 LIGAND; FEMALE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; RADIATION CHIMERA; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036378020     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01857.x     Document Type: Article

References (45)

1. Blazar BR, Taylor PA, Linsley PS et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994; 83:3815-25.
2. Wallace PM, Johnson JS, MacMaster JF et al. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58:602-10.
3. Durie FH, Aruffo A, Ledbetter J et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994; 94:1333-8.
4. Saito K, Yagita H, Hashimoto H et al. Effect of CD80 and CD86 blockade and anti- interleukin-12 treatment on mouse acute graft-versus-host disease. Eur J Immunol 1996; 26:3098-106.
5. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 1997; 158:29-39.
6. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-8.
7. Wekerle T, Sayegh MH, Hill J et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with co-stimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187:2037-44.
8. Li Y, Li XC, Zheng XX et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Med 1999; 5:1298-302.
9. Matulonis U, Dosiou C, Freeman G et al. B7-1 is superior to B7-2 co-stimulation in the induction and maintenance of T cell-mediated autileukemia immunity. J Immunol 1996; 156:1126-31.
10. Dilloo D, Brown M, Roskrow M et al. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997; 90:1927-33.
11. + T-cell line with potent in vivo graft-versus-leukemia properties. Blood 1997; 89:3477-85.
12. Nakajima A, Kodama T, Morimoto S et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumour responses by IL-12 and B7. J Immunol 1998; 161:1901-7.
13. Kato K, Cantwell MJ, Sharma S et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101:1133-41.
14. Blazar BR, Taylor PA, Boyer MW et al. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 1997; 159:3460-73.
15. + cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83:2560-9.
16. Hattori KH, Hirano T, Miyajima H et al. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic bone marrow transplantation. Br J Haematol 1999; 105:303-12.
17. Teshima T, Hill GR, Pan L et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999; 104:317-25.
18. Nakajima A, Azuma M, Kodera S et al. Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule. Eur J Immunol 1995; 25:3060-9.
19. Nuriya S, Yagita H, Okumura K et al. The differential role of CD86 and CD80 co-stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Int Immunol 1996; 8:917-26.
20. Slavin S, Strober S. Spontaneous murine B-cell leikemia. Nature 1978; 272:624-6.
21. + T cells. J Immunol 2000; 164: 664-9.
22. + T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 1999; 162:4373-6.
23. Saito K, Sakurai J, Ohata J et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 1998; 160: 4225-31.
24. Weiss L, Reich S, Slavin S. The role of antibodies to IL-2 receptor and asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia. Bone Marrow Transplant 1995; 16:457-61.
25. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol Immunother 1990; 31:236-42.
26. Cohen P, Vourka-Karussis U, Weiss L et al. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol 1993; 151:4803-10.
27. Weiss L, Lubin I, Factorowich I et al. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. J Immunol 1994; 153:2562-7.
28. Garza KM, Chan SM, Suri R et al. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 2000; 191:2021-7.
29. Diehl L, den Boer AT, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med 1999; 5:774-9.
30. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999; 5:780-7.
31. Howland KC, Ausubel LJ, London CA et al. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000; 164:4465-70.
32. Lefrancois L, Altman JD, Williams K et al. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 2000; 164:725-32.
33. Schuurhuis DH, Laban S, Toes RE et al. Immature dendritic cells acquire CD8 (+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 2000; 192:145-50.
34. + T cell tolerance and linked suppression. J Immunol 1999; 163:4805-10.
35. Taylor PA, Noelle RJ, Blazar BR. CD4 (+) CD25 (+) immune regulatory cells are required for induction of tolerance to alloantigen via co-stimulatory blockade. J Exp Med 2001; 193:1311-8.
36. Taylor PA, Lees CJ, Waldmann H et al. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001; 98:467-74.
37. Tang A, Judge TA, Turka LA. Blockade of CD40-CD40 ligand pathway induces tolerance in murine contact hypersensitivity. Eur J Immunol 1997; 27:3143-50.
38. Van Gool SW, Vermeiren J, Rafiq K et al. Blocking CD40-CD154 and CD80/CD86-CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production. Eur J Immunol 1999; 29:2367-75.
39. - T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150:1147-59.
40. Ramarathinam L, Castle M, Wu Y et al. T cell co-stimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection. an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994; 179:1205-14.
41. Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determinants the effect of B7 co-stimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179:523-32.
42. Shahinian A, Pfeffer K, Lee KP et al. Differential T cell co-stimulatory requirements in CD28-deficient mice. Science 1993; 261:609-12.
43. + T cells independently of the CD28/B7 and LFA-1/ICAM-1 co-stimulatory interactions. J Immunol 1998; 160:3180-7.
44. + T cells do not require co-stimulation for proliferation and differentiation into cytotoxic effector cells. J Immunol 2000; 164:1216-22.
45. + T cells. J Immunol 1999; 163:2358-62.